Related Experiment Video
Updated: Jun 7, 2026
05:46
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Implications of HIV PrEP trials results
Fulvia Veronese1, Peter Anton, Courtney V Fletcher
1Prevention Sciences Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA. veronesf@niaid.nih.gov
AIDS Research and Human Retroviruses
|October 26, 2010
Summary
Early results from six HIV pre-exposure prophylaxis (PrEP) trials using tenofovir disoproxil fumarate (TDF) prompt urgent discussions on adapting ongoing studies. Experts convened to analyze implications for future HIV prevention research.
Area of Science:
- Virology
- Clinical Trials
- Public Health
Background:
- Six randomized clinical trials evaluated tenofovir disoproxil fumarate (TDF) and TDF/emtricitabine (TDF/FTC) for HIV-1 pre-exposure prophylaxis (PrEP).
- Emerging results from these trials necessitate evaluating potential modifications to ongoing studies.
Framework:
- A workshop was convened to discuss the implications of early PrEP trial results.
- Sponsored by NIAID, NIH, and BMGF, the consultation included diverse experts in HIV research and regulation.
Implementation:
- Participants comprised basic scientists, clinical researchers, and representatives from regulatory and funding agencies.
- The workshop aimed to proactively address changes needed in ongoing PrEP trials based on emerging data.
Implications:
- The workshop facilitated a discussion on adapting HIV prevention strategies.
- Key topics included the impact of early findings on the design and conduct of future PrEP trials.
